A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: Biochemical, pharmacodynamic, pharmacokinetic, and safety profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 775-785

  Kim, Enoch ^a   Campbell, Stewart ^a   Schueller, Olivier ^a   Wong, Eric ^a   Cole, Bridget ^a   Kuo, Jay ^a   Ellis, James ^a   Ferkany, John ^a   Sweetnam, Paul ^a  

^a Surface Logix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' TRIFLUOROMETHYLBIPHENYL 2 CARBOXYLIC ACID[2 (2H [1,2,4]TRIAZOL 3 YLMETHYL) 1,2,3,4 TETRAHYDROISOQUINOLIN 6 YL]AMIDE; 6 (4' TRIFLUOROMETHYL 6 METHOXYBIPHENYL 2 YLCARBOXAMIDO) 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLIC ACID PHENYL ESTER; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CP 346086; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; SLX 4090; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BODY FAT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN CELL; INTESTINE CELL; LIPID DIET; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SINGLE DRUG DOSE; TOXICITY TESTING; WEIGHT REDUCTION;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BENZAMIDES; CACO-2 CELLS; CARRIER PROTEINS; CHOLESTEROL, LDL; DRUG EVALUATION, PRECLINICAL; FEMALE; HEPATOCYTES; HUMANS; ISOQUINOLINES; LIPID REGULATING AGENTS; LIVER; MALE; MICE; MICE, KNOCKOUT; PERMEABILITY; POSTPRANDIAL PERIOD; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRIAZOLES; TRIGLYCERIDES;

EID: 79956202758     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.177527     Document Type: Article

References (34)

1. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, and Fernandez ML (2005) JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers serum triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 5:30.
2. Anwar K, Iqbal J, and Hussain MM (2007) Mechanisms involved in vitamin E transport by primary enterocytes and in vivo absorption. J Lipid Res 48:2028-2038. (Pubitemid 47360622)
3. Bartolozzi A, Campbell A, Foudoulakis H, Kim E, Sweetnam P, and Yang Y (2008) inventors; Surface Logix, Inc., assignee. Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion. European patent EP1877369 (A2). 2008 Jan 16.
4. Borén J, Véniant MM, and Young SG (1998) Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 101:1197-1202. (Pubitemid 28145234)
5. Botham KM (2008) Oxidation of chylomicron remnants and vascular dysfunction. Atheroscler Suppl 9:57-61.
6. Cannon CP (2008) Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol 102:5L-9L.
7. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, and Harwood HJ Jr (2003) CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 44:1887-1901. (Pubitemid 37356661)
8. Ginsberg HN and MacCallum PR (2009) The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 4:113-119.
9. Gordon DA and Jamil H (2000) Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta 1486:72-83. (Pubitemid 30336793)
10. Gruetzmann R, Beuck M, Mueller U, and Nielsch U (2000) Bay 13-9952 (implitapide), an inhibitor of microsomal triglyceride transfer protein (MTP), blocks secretion of Apo-B lipoproteins. Atherosclerosis 151:91-92.
11. Hidalgo IJ, Raub TJ, and Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749. (Pubitemid 19057595)
12. Hussain MM and Bakillah A (2008) New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 19:572-578.
13. Lammens L, Borghys H, Roevens P, and Vandenberghe J (1999) Histological changes in liver and jejunum induced by R103757, a new inhibitor of microsomal triglyceride transfer protein (MTP). Atherosclerosis 144 (Suppl 1):39.
14. Li CM, Presley JB, Zhang X, Dashti N, Chung BH, Medeiros NE, Guidry C, and Curcio CA (2005) Retina expresses microsomal triglyceride transfer protein: implications for age-related maculopathy. J Lipid Res 46:628-640. (Pubitemid 43073272)
15. Li J, Bronk BS, Dirlam JP, Blize AE, Bertinato P, Jaynes BH, Hickman A, Miskell C, Pillai UA, Tibbitts JS, et al. (2007) In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity. Bioorg Med Chem Lett 17:1996-1999.
16. Lilly SM and Rader DJ (2007) New targets and emerging therapies for reducing LDL cholesterol. Curr Opin Lipidol 18:650-655. (Pubitemid 350098570)
17. Mansbach CM and Siddiqi SA (2010) The biogenesis of chylomicrons. Annu Rev Physiol 72:315-333.
18. Mattes RD (2009) Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans. Am J Physiol Gastrointest Liver Physiol 296: G365-G371.
19. Miyazaki, Miwa S, Kodama H, Yamada H, Nagata K, Toriumi W, Kitamura K, and Kume E (2007) Hepatic and intestinal changes in rats treated with T-0126, a microsomal triglyceride transfer protein (mtp) inhibitor. J Toxicol Sci 32:161-177. (Pubitemid 46849773)
20. Paulo MG, Marques HM, Morais JA, and Almeida AJ (1999) An isocratic LC method for the simultaneous determination of vitamins A, C, E and β-carotene. J Pharm Biomed Anal 21:399-406. (Pubitemid 29502578)
21. Phillips C, Mullan K, Owens D, and Tomkin GH (2006) Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 187:57-64. (Pubitemid 43833357)
22. Reiner Z (2010) Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 24:19-28.
23. Roevens P, Heeres J, Meerpoel L, Dupont A, Borghys H, Lammens L, Auwerx J, Staels B, and de Chaffoy de Courcelles D (1999) Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP). Atherosclerosis 144 (Suppl 1):38.
24. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, and Rader DJ (2008) Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 5:497-505.
25. Thomson AB, Cheeseman CI, Keelan M, Fedorak R, and Clandinin MT (1994) Crypt cell production rate, enterocyte turnover time and appearance of transport along the jejunal villus of the rat. Biochim Biophys Acta 1191:197-204. (Pubitemid 24133545)
26. Tietge UJ, Bakillah A, Maugeais C, Tsukamoto K, Hussain M, and Rader DJ (1999) Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res 40:2134-2139. (Pubitemid 29523440)
27. Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, and Couture P (2006) Effect of ezetimibe on the in vivo kinetics of ApoB-48 and apoB-100 in men with primary hypercholesterolemia. Atherioscler Thromb Vasc Biol 26:1101-1106. (Pubitemid 43732118)
28. Tushuizen ME, Pouwels PJ, Bontemps S, Rustemeijer C, Matikainen N, Heine RJ, Taskinen MR, and Diamant M (2010) Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. Atherosclerosis 211:308-314.
29. Ueshima K, Akihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, and Mutoh S (2005) Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Westerntype diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 28:247-252. (Pubitemid 40880003)
30. Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, and Davis HR Jr (1997) In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283:157-163.
31. Wetterau JR, Gregg RE, Harrity TW, Arbeeny C, Cap M, Connolly F, Chu CH, George RJ, Gordon DA, Jamil H, et al. (1998) An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282:751-754. (Pubitemid 28489389)
32. Wierzbicki AS, Hardman T, and Prince WT (2009) Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol 7:277-286.
33. Wren JA, Gossellin J, and Sunderland SJ (2007) Dirlotapide: a review of its properties and role in the management of obesity in dogs. J Vet Pharmacol Ther 30:11-16. (Pubitemid 46850030)
34. Xie Y, Newberry EP, Young SG, Robine S, Hamilton RL, Wong JS, Luo J, Kennedy S, and Davidson NO (2006) Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem 281:4075-4086. (Pubitemid 43847833)